Cambrex Corporation (CBM) vs. Immune Pharmaceuticals (NASDAQ:IMNP) Head-To-Head Review
Cambrex Corporation (NYSE: CBM) and Immune Pharmaceuticals (NASDAQ:IMNP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitabiliy, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Insider & Institutional Ownership
98.3% of Cambrex Corporation shares are held by institutional investors. Comparatively, 60.8% of Immune Pharmaceuticals shares are held by institutional investors. 2.5% of Cambrex Corporation shares are held by insiders. Comparatively, 6.7% of Immune Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Cambrex Corporation and Immune Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Cambrex Corporation and Immune Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cambrex Corporation presently has a consensus target price of $65.67, indicating a potential upside of 10.46%. Immune Pharmaceuticals has a consensus target price of $3.00, indicating a potential upside of 22.95%. Given Immune Pharmaceuticals’ higher possible upside, analysts clearly believe Immune Pharmaceuticals is more favorable than Cambrex Corporation.
Volatility and Risk
Cambrex Corporation has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cambrex Corporation and Immune Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cambrex Corporation||$500.61 million||3.87||$161.83 million||$2.63||22.60|
|Immune Pharmaceuticals||N/A||N/A||-$12.54 million||N/A||N/A|
Cambrex Corporation has higher revenue and earnings than Immune Pharmaceuticals.
Cambrex Corporation beats Immune Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.